J
Jerry M. Collins
Researcher at National Institutes of Health
Publications - 193
Citations - 12450
Jerry M. Collins is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Pharmacokinetics & Cancer. The author has an hindex of 59, co-authored 191 publications receiving 12009 citations. Previous affiliations of Jerry M. Collins include Food and Drug Administration & Georgetown University Medical Center.
Papers
More filters
Journal ArticleDOI
Administration of 3'-azido-3'-deoxythymidine, an inhibitor of htlv-iii/lav replication, to patients with aids or aids-related complex
Robert Yarchoan,Kent J. Weinhold,H. Kim Lyerly,Edward P. Gelmann,Robert M. Blum,Gene M. Shearer,Hiroaki Mitsuya,Jerry M. Collins,Charles E. Myers,Raymond W. Klecker,Phillip D. Markham,David T. Durack,S. Nusinoff Lehrman,David W. Barry,Margaret A. Fischl,Robert C. Gallo,Dani P. Bolognesi,Samuel Broder +17 more
TL;DR: 4 dose regimens of 3'-azido-3'-deoxythymidine (AZT), a thymidine analogue with potent anti-viral activity against HTLV-III in vitro, were examined in 19 patients with the acquired immunodeficiency syndrome (AIDS) or AIDS-related complex (ARC).
Journal ArticleDOI
Accelerated Titration Designs for Phase I Clinical Trials in Oncology
Richard M. Simon,Boris Freidlin,Larry Rubinstein,Susan G. Arbuck,Jerry M. Collins,Michaele C. Christian +5 more
TL;DR: Accelerated titration (i.e., rapid intrapatient drug dose escalation) designs appear to effectively reduce the number of patients who are under-treated, speed the completion of phase I trials, and provide a substantial increase in the information obtained.
Journal ArticleDOI
Phase i studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (azt)
Robert Yarchoan,Rose V. Thomas,Jean-Pierre Allain,Nanette McAtee,Richard Dubinsky,Hiroaki Mitsuya,Thomas J. Lawley,Bijan Safai,Charles E. Myers,Carlo Federico Perno,Raymond W. Klecker,Robert J. Wills,Margaret A. Fischl,M. Carol Mcneely,James M. Pluda,Michael Leuther,Jerry M. Collins,Samuel Broder +17 more
TL;DR: It is suggested that ddC has activity against HIV in vivo and has a different toxicity profile from that of zidovudine (AZT).
Journal ArticleDOI
Plasma and cerebrospinal fluid pharmacokinetics of 3'-azido-3'-deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases.
Raymond W. Klecker,Jerry M. Collins,Robert Yarchoan,Rose V. Thomas,Jean Jenkins,Samuel Broder,Charles E. Myers +6 more
TL;DR: N3TdR possesses pharmacokinetic properties that would facilitate the long‐term treatment of patients with acquired immunodeficiency syndrome: it can be given orally and it penetrates the central nervous system.
Journal ArticleDOI
Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies
Shivaani Kummar,Robert J. Kinders,Martin Gutierrez,Larry Rubinstein,Ralph E. Parchment,Lawrence R. Phillips,Jiuping Ji,Anne Monks,Jennifer A. Low,Alice P. Chen,Anthony J. Murgo,Jerry M. Collins,Seth M. Steinberg,Helen Eliopoulos,Vincent L. Giranda,Gary B. Gordon,Lee J. Helman,Robert H. Wiltrout,Joseph E. Tomaszewski,James H. Doroshow +19 more
TL;DR: The rapid conclusion of this trial demonstrates the feasibility of conducting proof-of-principle phase 0 trials as part of an alternative paradigm for early drug development in oncology.